Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of arlocabtagene autoleucel versus standard therapy in lenalidomide-exposed relapsed or refractory multiple myeloma
NL-OMON59418Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of arlocabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Progression-free survival and MRD-negative complete response. Started Jul 2025; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59418.